Isoliquiritigenin suppresses the proliferation and induced apoptosis via miR-32/LATS2/Wnt in nasopharyngeal carcinoma
- 1 August 2019
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 856, 172352
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Shikonin Inhibits Thyroid Cancer Cell Growth and Invasiveness Through Targeting Major Signaling PathwaysThe Journal of Clinical Endocrinology & Metabolism, 2013
- Inhibitory effects of isoliquiritigenin on the migration and invasion of human breast cancer cellsExpert Opinion on Therapeutic Targets, 2013
- LATS tumor suppressor: A new governor of cellular homeostasisCell Cycle, 2010
- Isoliquiritigenin, a natural anti‐oxidant, selectively inhibits the proliferation of prostate cancer cellsClinical and Experimental Pharmacology and Physiology, 2010
- Clinical Efficacy of Traditional Chinese Medicine as a Concomitant Therapy for Nasopharyngeal Carcinoma: A Systematic Review and Meta-AnalysisCancer Investigation, 2009
- Isoliquiritigenin inhibits IκB kinase activity and ROS generation to block TNF-α induced expression of cell adhesion molecules on human endothelial cellsBiochemical Pharmacology, 2007
- Intensity‐modulated or conformal radiotherapy improves the quality of life of patients with nasopharyngeal carcinomaCancer, 2007
- Activation of MMP‐2 and MMP‐9 in patients with oral squamous cell carcinomaJournal of Surgical Oncology, 2005
- Nasopharyngeal carcinomasEuropean Journal of Cancer, 2003
- ANTIAPOPTOTIC PROTEINSCardiology Clinics, 2001